MarketPeel
Insider Trading Intelligence
Pricing
…
VL

Vhcp Management Eg, Llc

KALV
10% OWNER · KALVISTA PHARMACEUTICALS, INC. · CIK 0001808518
FILING MIX · LIFETIME86%/14%
BUYS
38
SELLS
6
TOTAL VALUE
$34.59M
COMPANIES
3
ACTIVE SINCE
Jul 2022
HOLDINGS NOW
29,875,068
AVG SELL PX
$13.63
TRADE KIND
SHOWING 44 / 44
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
44 backtested trades · 8 horizons · 29 pending
Forward-return performance of every backtestable P/S trade by Vhcp Management Eg, Llc, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d44+61.36%+4.76%+0.59%+4.17%+3.26%3.30
14d44+61.36%+4.81%+1.07%+3.74%+5.99%1.47
30d44+68.18%+9.63%+1.84%+7.79%+8.49%2.37
60d44+40.91%+3.29%+0.87%-3.23%-11.82%-0.78
90d44+25.64%-3.06%+4.12%-5.97%-15.51%-1.31
180d44(5 pending)+64.10%+10.82%+11.39%-0.57%-2.38%-0.14
1y44(5 pending)+38.46%+17.47%+21.62%-4.16%-55.81%-0.31
2y44(19 pending)+92.00%+14.90%+45.55%-30.65%-23.93%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
KALV · 5,089,354 shares · as of Mar 26, 2026
01,325,9962,651,9933,977,9895,303,985202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 38 buys / 6 sellsCOVERAGE · 15 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
KALV
KALVISTA PHARMACEUTICALS, INC.
SALE
15,417$18.82$290.1K5,092,537Mar 26, 2026Mar 27, 2026 ↗View →
KALV
KALVISTA PHARMACEUTICALS, INC.
SALE
21,386$17.76$379.8K5,107,954Mar 26, 2026Mar 27, 2026 ↗View →
KALV
KALVISTA PHARMACEUTICALS, INC.
SALE
3,183$19.12$60.9K5,089,354Mar 26, 2026Mar 27, 2026 ↗View →
KALV
KALVISTA PHARMACEUTICALS, INC.
SALE
160$17.53$2.8K5,129,340Mar 25, 2026Mar 27, 2026 ↗View →
KALV
KALVISTA PHARMACEUTICALS, INC.
SALE
174,485$16.95$2.96M5,129,500Mar 25, 2026Mar 27, 2026 ↗View →
KALV
KALVISTA PHARMACEUTICALS, INC.
PURCHASE
25,000$9.42$235.5K5,303,985Apr 9, 2025Apr 11, 2025 ↗View →
ORKA
ORUKA THERAPEUTICS, INC.
PURCHASE
88,794$11.44$1.02M4,148,428Feb 14, 2025Feb 27, 2025 ↗View →
KALV
KALVISTA PHARMACEUTICALS, INC.
PURCHASE
61,700$9.33$575.7K5,278,985Feb 13, 2025Feb 14, 2025 ↗View →
ORKA
ORUKA THERAPEUTICS, INC.
PURCHASE
14,950$11.63$173.9K4,059,634Feb 13, 2025Feb 27, 2025 ↗View →
KALV
KALVISTA PHARMACEUTICALS, INC.
PURCHASE
100,000$9.23$923.0K5,217,285Feb 12, 2025Feb 14, 2025 ↗View →
ORKA
ORUKA THERAPEUTICS, INC.
PURCHASE
8,971$11.86$106.4K4,044,684Feb 12, 2025Feb 27, 2025 ↗View →
KALV
KALVISTA PHARMACEUTICALS, INC.
PURCHASE
26,703$9.18$245.1K5,117,285Feb 11, 2025Feb 11, 2025 ↗View →
ORKA
ORUKA THERAPEUTICS, INC.
PURCHASE
9,593$10.95$105.0K4,035,713Feb 11, 2025Feb 27, 2025 ↗View →
KALV
KALVISTA PHARMACEUTICALS, INC.
PURCHASE
4,137$9.14$37.8K5,090,582Feb 10, 2025Feb 11, 2025 ↗View →
ORKA
ORUKA THERAPEUTICS, INC.
PURCHASE
574$10.90$6.3K4,026,120Feb 10, 2025Feb 27, 2025 ↗View →
KALV
KALVISTA PHARMACEUTICALS, INC.
PURCHASE
73,649$9.29$684.2K5,086,445Feb 7, 2025Feb 11, 2025 ↗View →
KALV
KALVISTA PHARMACEUTICALS, INC.
PURCHASE
14,562$9.22$134.3K5,012,796Feb 3, 2025Feb 3, 2025 ↗View →
KALV
KALVISTA PHARMACEUTICALS, INC.
PURCHASE
11,754$8.89$104.5K4,998,234Jan 31, 2025Feb 3, 2025 ↗View →
KALV
KALVISTA PHARMACEUTICALS, INC.
PURCHASE
43,707$8.76$382.9K4,986,480Jan 30, 2025Feb 3, 2025 ↗View →
KALV
KALVISTA PHARMACEUTICALS, INC.
PURCHASE
655,738$15.25$10.00M655,738Feb 20, 2024Feb 22, 2024 ↗View →
KALV
KALVISTA PHARMACEUTICALS, INC.
PURCHASE
29,747$14.70$437.3K4,824,731Feb 8, 2024Feb 8, 2024 ↗View →
KALV
KALVISTA PHARMACEUTICALS, INC.
PURCHASE
51,827$14.56$754.6K4,794,984Feb 7, 2024Feb 8, 2024 ↗View →
KALV
KALVISTA PHARMACEUTICALS, INC.
PURCHASE
4,474$14.74$65.9K4,743,157Feb 6, 2024Feb 8, 2024 ↗View →
KALV
KALVISTA PHARMACEUTICALS, INC.
PURCHASE
88,099$14.47$1.27M4,738,683Jan 30, 2024Feb 1, 2024 ↗View →
KALV
KALVISTA PHARMACEUTICALS, INC.
PURCHASE
80,600$14.22$1.15M4,650,584Jan 29, 2024Jan 29, 2024 ↗View →
KALV
KALVISTA PHARMACEUTICALS, INC.
PURCHASE
4,174$12.98$54.2K4,569,984Jan 26, 2024Jan 29, 2024 ↗View →
KALV
KALVISTA PHARMACEUTICALS, INC.
PURCHASE
7,030$12.73$89.5K4,565,810Jan 25, 2024Jan 29, 2024 ↗View →
KALV
KALVISTA PHARMACEUTICALS, INC.
PURCHASE
20,686$12.44$257.3K4,558,780Jan 24, 2024Jan 24, 2024 ↗View →
KALV
KALVISTA PHARMACEUTICALS, INC.
PURCHASE
10,897$12.54$136.6K4,538,094Jan 23, 2024Jan 24, 2024 ↗View →
KALV
KALVISTA PHARMACEUTICALS, INC.
PURCHASE
67,546$12.55$847.7K4,527,197Jan 22, 2024Jan 24, 2024 ↗View →
KALV
KALVISTA PHARMACEUTICALS, INC.
PURCHASE
25,000$12.43$310.8K4,459,651Jan 19, 2024Jan 19, 2024 ↗View →
KALV
KALVISTA PHARMACEUTICALS, INC.
PURCHASE
39,680$12.51$496.4K4,434,651Jan 18, 2024Jan 19, 2024 ↗View →
KALV
KALVISTA PHARMACEUTICALS, INC.
PURCHASE
78,925$12.60$994.5K4,394,971Jan 17, 2024Jan 19, 2024 ↗View →
KALV
KALVISTA PHARMACEUTICALS, INC.
PURCHASE
19,599$12.73$249.5K4,316,046Jan 16, 2024Jan 16, 2024 ↗View →
KALV
KALVISTA PHARMACEUTICALS, INC.
PURCHASE
6,647$12.68$84.3K4,296,447Jan 11, 2024Jan 16, 2024 ↗View →
KALV
KALVISTA PHARMACEUTICALS, INC.
PURCHASE
47,700$12.67$604.4K4,289,800Jan 10, 2024Jan 10, 2024 ↗View →
KALV
KALVISTA PHARMACEUTICALS, INC.
PURCHASE
20,816$12.56$261.4K4,242,100Jan 9, 2024Jan 10, 2024 ↗View →
KALV
KALVISTA PHARMACEUTICALS, INC.
PURCHASE
69,184$12.44$860.6K4,221,284Jan 8, 2024Jan 10, 2024 ↗View →
KALV
KALVISTA PHARMACEUTICALS, INC.
PURCHASE
41,764$12.11$505.8K4,152,100Jan 4, 2024Jan 5, 2024 ↗View →
KALV
KALVISTA PHARMACEUTICALS, INC.
PURCHASE
17,605$12.20$214.8K4,110,336Jan 3, 2024Jan 5, 2024 ↗View →
KALV
KALVISTA PHARMACEUTICALS, INC.
PURCHASE
6,013$12.49$75.1K4,092,731Dec 29, 2023Dec 29, 2023 ↗View →
KALV
KALVISTA PHARMACEUTICALS, INC.
PURCHASE
471,490$12.50$5.89M4,086,718Dec 28, 2023Dec 29, 2023 ↗View →
KALV
KALVISTA PHARMACEUTICALS, INC.
PURCHASE
41,514$11.97$496.9K3,615,228Dec 27, 2023Dec 29, 2023 ↗View →
VTGN
VISTAGEN THERAPEUTICS, INC.
SALE
60,000$0.89$53.4K20,637,286Jul 12, 2022Jul 14, 2022 ↗View →
Other insiders · KALV
Loading peer insiders…
About this filer
CIK 0001808518
ROLE
10% Owner
PRIMARY
KALV
COMPANIES
3
ACTIVE SINCE
Jul 2022
MARKETPEEL · /INSIDER/0001808518DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback